Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CETROTIDE

« Back to Dashboard
Cetrotide is a drug marketed by Emd Serono Inc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty-two countries.

The generic ingredient in CETROTIDE is cetrorelix. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cetrorelix profile page.

Summary for Tradename: CETROTIDE

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Clinical Trials for: CETROTIDE

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation
Status: Completed Condition: Infertile Women Undergoing Assisted Reproductive Technology (ART)

Cetrotide Treatment Optimization
Status: Terminated Condition: In Vitro Fertilization; Intracytoplasmic Sperm Injection

An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
Status: Completed Condition: Infertility

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Status: Completed Condition: Polycystic Ovarian Syndrome

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Status: Completed Condition: Ovarian Hyperstimulation Syndrome

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Status: Completed Condition: Benign Prostatic Hypertrophy

Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Status: Terminated Condition: Benign Prostatic Hypertrophy

Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Status: Completed Condition: Benign Prostatic Hypertrophy

GnRH Antagonist to Prepare Recipients for Embryo Transfer
Status: Completed Condition: Infertility

A Multinational, Randomized, Double-Blind, Placebo‑Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Status: Completed Condition: Endometriosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000RXYes6,319,192<disabled> <disabled>
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000DISCNNo6,319,192<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CETROTIDE

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 20004,800,191<disabled>
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 20007,605,121<disabled>
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 20006,863,891<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CETROTIDE

Country Document Number Publication Date
Slovenia1082129Feb 29, 2004
Hungary228736May 28, 2013
New Zealand507405Oct 25, 2002
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc